Hangzhou Wutongshu Pharmaceutical

Hangzhou Wutongshu Pharmaceutical is a Chinese biotechnology company established in 2017 and headquartered in Hangzhou. The company specializes in the research and development of innovative therapies for oncology, immune system diseases, and metabolic disorders. It operates through a collaborative R&D model, leveraging the technical expertise of the Sichuan University State Key Laboratory of Biotherapy and strategic partnerships with WuXi AppTec. Its clinical pipeline features lead candidates such as ILB-2109, an A2aR antagonist co-developed with InnoLake Biopharm, and WTS-004, an EGFR inhibitor targeting non-small cell lung cancer with central nervous system metastases. Wutongshu aims to address significant unmet medical needs through a diverse portfolio of small molecules, biological preparations, and gene therapies.